Global, full-service delivery for complex psychedelic trials

ICON is delivering a large scale, multinational clinical programme evaluating a psychedelic investigational drug in a complex psychiatric indication. The programme spans more than 150 investigative sites across North America and Europe, involves multiple vendors, and is delivered as a full service offering to the study sponsor.

Highly complex site activation requirements

The study protocols included a range of unique requirements for site infrastructure, staffing, and training necessitating extensive upfront site outreach, verification against multiple suitability criteria, and ongoing engagement to address site questions. 

Despite careful pre-selection, several initially identified sites were ultimately unable to participate due to the complexity of the requirements. To reach readiness for patient screening, participating sites were required to complete an extensive set of activities, including installation of specialised equipment, rater certification, and acquisition of controlled substance licences. 

Complex and evolving regulatory landscape

Regulatory submissions were particularly challenging due to multiple countries with diverse, national requirements, the early phase of EU CTR adoption, and a high volume of patient facing documentation. The protocols underwent several amendments during the early stages of the programme, further increasing regulatory complexity. Given the nature of the investigational product, the risk of regulatory questions or rejections was significant. 

Schedule I controlled substance management 

In this double blind study, the investigational product was classified as a Schedule I controlled substance. Investigators and site pharmacies were therefore required to obtain licences for drug storage and administration. 

In addition, cross border movement of the investigational product between depots and sites required shipment specific import and export licences. Country specific chain of custody requirements added further complexity to investigational product management at both depot and site levels.

Tailored site selection and accelerated activation

ICON conducted extensive site selection to identify experienced, capable sites across all participating countries. Given the scale of the study, many sites were new to psychedelic research. 

Our Start Up and Clinical Operations teams defined site specific critical paths to activation, allowing effort and resources to be focused where they would have the greatest impact. Early and continuous engagement with the sponsor supported site motivation and ensured rapid resolution of issues. 

ICON Clinical Trial Managers led and coordinated the activation process, ensuring requirements were addressed in parallel and proactively preparing for activation while regulatory approvals and licenses were still pending. 

Aligned global regulatory strategy 

ICON’s Regulatory team developed a coordinated global submission strategy, ensuring alignment across all participating countries. Submission packages were standardised wherever possible and customised as needed to meet local requirements, reducing the likelihood of regulatory queries. 

EU CTR submissions were strategically planned to optimise site recruitment timelines while avoiding unnecessary country specific protocol versions, supporting faster study start up. 

Proactive management of investigational product logistics 

At the site level, controlled substance licences were frequently on the critical path for activation. ICON teams prioritised these applications and guided less experienced sites through the process, including detailed reviews of submission packages for completeness and accuracy. 

ICON Clinical Supplies Management developed a comprehensive Pharmacy Manual outlining country specific procedures for investigational product handling in compliance with local controlled substance regulations. During the maintenance phase, ICON Clinical and Clinical Supplies teams provided ongoing oversight of license renewals, chain of custody, storage conditions, and product returns. 

Globally, ICON Clinical Supplies worked closely with a specialised distribution partner to ensure uninterrupted investigational product supply. This included maintaining appropriate inventory at depots and sites, securing regulatory permits for international shipments, and managing multiple labeling and packaging campaigns.

Regulatory approvals were secured across all participating countries, and the majority of selected sites were successfully activated and contributed to enrolment. 

As the programme progressed, ICON strengthened its focused, proactive approach to site activation, enabling sites to reach readiness for patient screening, including receipt of Schedule I licenses, in as little as three months from site selection, despite the extraordinary regulatory and operational complexity of the programme.

Through this programme, ICON has strengthened relationships with psychiatric research sites that have developed deep expertise in psychedelic clinical trials. ICON’s comprehensive understanding of the regulatory, operational, and logistical interdependencies unique to these studies, combined with ICON’s established CNS expertise, positions us to efficiently select, activate, and support sites in future psychedelic research programmes, accelerating timelines and enabling faster access to innovative therapies.